We identified a novel nonsense mutation(R29X) of the MEN1 gene in a familial multiple endocrine neoplasia type 1 (MEN1) patient.
FAMILIAL
multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant inherited disorder characterized by tumors of the parathyroid, anterior pituitary and gastro-enteropancreatic endocrine tissues [ 1, 2] . The gene responsible for MEN1 has been localized to chromosome 11q13, and has frequently demonstrated loss of heterozygosity (LOH) in tumors in MEN1 patients [3, 4] . Genetic screening studies in the family members of MEN1 patients that have used polymorphic DNA markers of the MEN1 locus at 11q13 have identified the carrier state of MEN1 [5] [6] [7] [8] , but this screening strategy is insufficient to identify MEN1, because it does not directly examine the gene responsible for MEN1.
Recently the MEN1 gene as a tumor suppressor gene was cloned [9, 10] , and various heterozygous germline mutations of this gene were detected in MEN1 and related states in many individuals with MEN1 [9] [10] [11] [12] [13] [14] . In the present report, we examined the MEN1 germline mutation in Japanese familial MEN1, and a novel nonsense mutation of the MEN1 gene was detected in the subclinical state of MEN1 as well as clinical MEN1 in this family member.
Subjects and Methods
Report of a proband case and MEN1 family members
The pedigree of the MEN1 family examined in the present report is shown in Fig. 1 . They are Japanese and reside in Kagawa Prefecture. This pedigree was based on interviews, questionnaires and clinical examinations.
The main clinical findings for the 6 cases in this family are given in Table 1 . The proband (case 3) had been followed avoid malignant transformation and bleeding peptic ulcer disease [15] . Usually the clinical screening of MEN1 has been performed by means of biochemical, hormonal, and imaging examinations [16] .
Previous studies have reported genetic screening studies in the family members of MEN1 that used polymorphic DNA markers of the MEN1 locus at 11q13, and indicated gene carriers [5] [6] [7] [8] , but this screening method examines the responsible gene of MEN1 indirectly.
On the other hand, we used a direct and simple method to screen for the MEN1 gene mutation.
Genetic analysis of the MEN1 gene is a useful tool that allows screening for early diagnosis of MEN1 in family members, when the MEN1 gene mutation is detected in the proband. It seems to be possible to prevent progress of the disease by a combination of genetic examination and early treatment. Four family members including the proband were positive for the MEN1 gene mutation in this study. Case 2, the elder brother of the proband was without mutation and case 4, the younger brother of the proband, was with mutation.
This confirms the autosomal dominant inheritance of the MEN1 gene mutation in this family, because the theoretical probability of the gene transfer is 50%.
Various mutations including missense, nonsense and frameshift mutations have been detected with high prevalence in the MEN1 gene and about 40% of them have been observed dominantly in exon 2 [9-141.
We identified a novel heterozygous nonsense mutation (R29X) of the MEN1 gene in this family in exon 2. These observations suggest that exon 2 of the MEN1 gene may be the first target region for diagnosis.
On the other hand, an R29X mutation results in the loss of its function, and will lead to MEN1. The function of the MEN1 gene is thought to be that of a tumor suppressor gene at present [9] , but the function of the MEN1 gene protein including its domain region is not known.
Further study is necessary to analyze its function.
MEN1 phenotypes were different in cases 3, 4 and 5 in the present study, although they had the same mutation of the MEN1 gene. Cases 3 and 4 had a non-functional tumor of both the pituitary and pancreas, but case 5 had pituitary prolactinoma and pancreatic insulinoma.
Previous reports have also indicated different phenotypes in family members carrying the same mutation [11, 12, 14 
